TrialPhase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
Trial details
- Registry ID
- NCT04072315
- Phase
- Phase 2
PLRX
Pliant Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
1Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/NCT04072315 | PLRX | Phase 2 | Completed | 2022-06-27Actual |
| Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisNCT04396756 | PLRX | Phase 2 | Completed | 2023-02-01Actual |
| Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)NCT04480840 | PLRX | Phase 2 | Completed | 2024-02-26Actual |
| Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)NCT05621252 | PLRX | Phase 2 | Completed | 2023-12-27Actual |
| Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisNCT06097260 | PLRX | Phase 2 | Terminated | 2025-04-04Actual |
Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis
Trial details
- Registry ID
- NCT04396756
- Phase
- Phase 2
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
Trial details
- Registry ID
- NCT04480840
- Phase
- Phase 2
Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Trial details
- Registry ID
- NCT05621252
- Phase
- Phase 2
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Trial details
- Registry ID
- NCT06097260
- Phase
- Phase 2
Latest recorded trial changes
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260 · Pliant Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: To characterize the effect of bexotegrast versus placebo on the change in forced vital capacity (FVC) in participants with idiopathic pulmonary fibrosis (IPF)
+ After
Measure: Change From Baseline in Forced Vital Capacity at Week 52